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Abstract
Despite the recent progress in the broad-scaled analysis of
proteins in body fluids, there is still a lack in protein profiling
approaches for biomarkers of rare diseases. Scarcity of samples is
the main obstacle hindering attempts to apply discovery driven
protein profiling in rare diseases. We addressed this challenge by
combining samples collected within the BIO-NMD consortium from
four geographically dispersed clinical sites to identify protein
markers associated with muscular dystrophy using an antibody
bead array platform with 384 antibodies. Based on concordance in
statistical significance and confirmatory results obtained from
analysis of both serum and plasma, we identified eleven proteins
associated with muscular dystrophy, among which four proteins
were elevated in blood from muscular dystrophy patients:
carbonic anhydrase III (CA3) and myosin light chain 3 (MYL3), both
specifically expressed in slow-twitch muscle fibers and mitochon-
drial malate dehydrogenase 2 (MDH2) and electron transfer flavo-
protein A (ETFA). Using age-matched sub-cohorts, 9 protein
profiles correlating with disease progression and severity were
identified, which hold promise for the development of new clinical
tools for management of dystrophinopathies.
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Introduction
A plethora of proteomics tools, including mass spectrometry and
affinity-based protein profiling approaches, is being increasingly
applied for analysis of body fluids, which aim to reveal many new
candidate biomarkers for diagnosis, prognosis, or surveillance of,
for example, most common cancer types with high incidence rates.
An equally urgent need for such protein markers exists also in rare
diseases, which are defined as affecting one person in every several
thousands or millions. Sample availability is, however, a limiting
factor and the main impediment to progress of research in rare
diseases, resulting in a remarkable lack of attempts to apply protein
profiling approaches in the quest for protein markers in rare
diseases.
One such example is Duchenne muscular dystrophy (DMD),
which is a rare X-linked genetic disease with an incidence rate of
1:5,000 in Wales and 1:6,000 in Ohio, as estimated by screening of
newborn male subjects (Kalman et al, 2011; Mendell et al, 2012;
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Moat et al, 2013). DMD is caused by frame-disrupting mutations in
the gene coding for dystrophin, resulting in loss of dystrophin.
Affected boys typically present in the first few years of life with
features suggestive of muscle weakness and often with global devel-
opmental delay. Progressive muscle weakness leads to loss of ambu-
lation by the age of 10, and if untreated, to fatal cardiorespiratory
insufficiency by the late teens. Becker muscular dystrophy (BMD) is
the milder allelic form of the disease with an incidence rate of
1:20,000 (Bushby et al, 1991; Moat et al, 2013). BMD is character-
ized by mutations that leave the open-reading frame intact, resulting
in the presence of internally deleted and often reduced levels of
dystrophin (Mercuri & Muntoni, 2013). Males affected by BMD pres-
ent later in life than those with DMD, mostly with a variable degree
of exercise intolerance, and despite progression, BMD patients are
usually able to remain ambulant until late in adult life.
Establishing a correct diagnosis in dystrophinopaties (DMD and
BMD) requires a multidisciplinary approach involving pediatricians,
geneticists and neurologists to define the severity of the clinical
phenotype by means of genetic, enzymatic and immunohistochemi-
cal tests (Manzur & Muntoni, 2009; Bushby et al, 2010; Verma et al,
2010; Ferlini et al, 2013). Dystrophin is invariably absent on muscle
biopsy from DMD patients, whereas BMD patient muscle biopsies
show dystrophin albeit at reduced levels or in a mosaic pattern
(Mercuri & Muntoni, 2013). Creatine kinase (CK) levels in blood,
elevated for both DMD and BMD, are also indicative of muscle
damage. However, it does not correlate well with disease severity,
being influenced by multiple factors such as amount of muscle
mass, age and level of physical activity (Malm et al, 2000; Baird
et al, 2012). Currently, disease progression and response to poten-
tial treatment are monitored by clinical assessments via consoli-
dated functional outcome measures and invasive testing using
muscle biopsies. Muscle magnetic resonance imaging (MRI) is being
under development and may hold promise as a noninvasive tool
(Mazzone et al, 2013). However, MRI is expensive and not suited
for young children unless sedated or anaesthetized, which is not
desirable in muscular dystrophy. Given that multiple clinical trials
are ongoing or planned in DMD (Rodino-Klapac et al, 2013), it is
important to develop new outcome measures correlating with
disease severity. Molecular biomarkers present in body fluids such
as proteins or microRNA (Cacchiarelli et al, 2011a,b) would be ideal
to monitor patient health status and, if validated, could also be used
for disease and patient stratification for clinical trials.
To explore the possibility of identifying circulating candidate
protein markers in rare diseases, we applied an affinity-proteomics
approach to generate proteomic signatures in blood of muscular
dystrophy patients and controls. A total of 345 blood samples
collected by the EU-FP7 BIO-NMD consortium partners (www.bio-
nmd.eu) from four clinical sites in Europe were profiled using a
multiplexed antibody suspension bead array for 315 unique proteins
targeted by 384 antibodies, all generated within the Human Protein
Atlas (www.proteinatlas.org) (Uhle´n et al, 2010; Fagerberg et al,
2013). Across the different center collections and blood preparation
types, data analysis yielded eleven protein profiles that consistently
differed between muscular dystrophy phenotypes and controls.
These profiles belonged almost exclusively to proteins involved in
muscle function and regeneration or are annotated as being specifi-
cally expressed in muscle tissue. These discovered protein profiles
may serve as a starting point for development of clinical blood tests
to facilitate stratification and disease monitoring in dystrophinopa-
thies, and the presented affinity-proteomics approach exemplifies a
strategy toward the identification of blood-based protein biomarkers
in rare diseases.
Results
Study and experimental design
We have here employed an affinity-proteomics approach using
highly multiplexed antibody suspension bead arrays for proteomic
profiling of serum and plasma samples. This setup is particularly
favorable in the context of rare diseases affecting very young
patients, as it requires only microliter amounts of sample material
to generate protein profiles in serum and plasma. The concept of
our approach is schematically presented in Fig 1A. The antibodies
were coupled to color-coded magnetic beads, mixed to create an
antibody array in suspension which was incubated with the non-
fractionated, biotin-labeled samples to generate protein profiles in
serum and plasma samples (Schwenk et al, 2008). The study was
carried out with a focus on samples collected within the EU-FP7
BIO-NMD project (www.bio-nmd.eu). For this purpose, four clinical
sites collected 345 samples from four different diagnostic categories
of sample donors: DMD patients, BMD patients, healthy controls
and asymptomatic female carriers (Fig 1A, Table 1). This geographi-
cally dispersed and, in this rare-disease context, large sample collec-
tion included various phenotypes, controls and blood preparation
types. We performed both intra- and inter-cohort comparisons of
samples from patients with different degrees of disease severity and
focused especially on concordant protein profiles in the two differ-
ent blood preparation types of serum and plasma and across the
different cohorts (Fig 1B).
Regarding the design of the antibody array, a hypothesis-driven
target selection approach was utilized, which was based on thor-
ough mining of different data sources such as experimental
evidence, pathway association, protein characteristics, and avail-
ability of validated antibodies within the Human Protein Atlas. For
this purpose, a list of genes was compiled together with defined
parameters including experimental evidence on protein or transcript
level and/or the degree of association level of genes with muscular
dystrophy. Existing experimental evidence on protein level by high-
throughput LC-MS/MS techniques and immunoassays; on transcript
level by RNA-seq; and on gene level by sequencing of single-
nucleotide polymorphisms from analyses of samples from DMD
patients with different phenotypes and/or response to steroid treat-
ment was included. Values for each parameter were normalized on
a scale of 0–1, each parameter was then multiplied by the given
weight (40% for experimental evidence), and the weighted scores
were summed. For each gene, additional parameters were included
regarding their expression in normal muscle tissue estimated by
immunohistochemistry; involvement in cellular pathways associ-
ated with muscular dystrophy, muscle contraction, sarcolemmal
stability, and energy metabolism based on gene/protein annotation
in curated databases; association to muscular dystrophy based on
literature mining and accessibility in body fluids (Yuryev et al,
2006). As described above, values were attributed to each parameter
and then weighted with 10% for all parameters except for the last
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one, which was weighted with 2.5%. Nine hundred and fifty-nine
unique gene entries were finally ranked based on the summed
weighted scores, and the top 315 genes with available validated
antibodies from the Human Protein Atlas were selected. Only anti-
bodies validated by Western blot and protein microarray were
considered.
Information regarding technical aspects of the assay, such as the
signal intensity distributions in serum and plasma (Supplementary
Figs S1A and S2), the technical quality of the assay in terms of intra-
assay % of coefficient of variations (CV) (Supplementary Fig S1B),
the number of antibodies revealing signal intensities at noise level
(Supplementary Table S1), and the number of correlating antibody
pairs targeting different parts of same protein in plasma and serum
(Supplementary Fig S3), is available as supplementary information.
Analysis of protein profiles within and across different cohorts
Analysis of the protein profiles from a global perspective by
performing unsupervised hierarchical clustering of the entire dataset
revealed that protein profiles were grouped mainly by blood prepa-
ration type (serum versus plasma) (Supplementary Figs S4 and
S5A). Comparative analysis between disease and control groups
was therefore carried out within each cohort and blood preparation
type for identification of concordant differential protein profiles
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Figure 1. Overview of the affinity proteomics-based screening approach and study setup.
A An antibody suspension bead array platform was utilized to obtain profiles for 315 unique proteins in a total of 345 serum/plasma samples collected within the BIO-
NMD project at different sites.
B The captured proteins in serum/plasma using the antibodies generated within the Human Protein Atlas were analyzed and based on the obtained protein profiles,
several inter- and intra-cohort comparisons in terms of diagnosis type and clinical parameters were performed.
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(Fig 1B). The main contributors to the separation of patient and
control groups in the different cohorts were proteins involved either
in muscle-specific functions such as myosin light chain 3 (MYL3),
calsequestrin-2 (CASQ2), microtubule-associated protein 4 (MAP4),
or proteins highly expressed in muscle tissue such as carbonic anhy-
drase 3 (CA3) and malate dehydrogenase 2 (MDH2) (Fig 2). This
supports the hypothesis of muscle proteins leaking into the blood-
stream as a consequence of muscle wasting through disruption of
the sarcolemma (Straub et al, 1997). Proteins involved in stress
response such as matrix metalloproteinase 9 (MMP9), Parkinson
disease protein 7 (PARK7) and proteins involved in metabolic
processes such as rho-related BTB domain-containing protein 1
(RHOBTB1), creatine kinase (CK), electron transfer flavoprotein A
and B (ETFA, ETFB) also contributed significantly to the discrimina-
tion between patients and controls.
Separation of DMD patients from controls was achieved within all
cohorts, and the protein profiles of CA3 and MYL3 were the main
common contributors (Fig 2). These two proteins together with CK,
MDH2, and ETFA were main contributors for separating NMD
patients and healthy controls in the UNIFE cohort (Fig 2A) and
together with only MDH2 for the clustering of DMD serum samples
and aged matched healthy donors in the LUMC cohort (Fig 2B). In
the UNEW cohort, CA3 and MYL3 profiles contributed for clustering
in both plasma and serum samples of DMD patients in comparison
with female carriers. Comparison of the two muscular dystrophy
phenotypes, DMD and BMD, in the UNEW cohort revealed again CA3
as an important contributor for the separation of these two patient
groups (Fig 2C and D) and MDH2 and MYL3 for separation of the
BMD patients and female carriers in both blood preparation types.
Protein profiles that contributed to the clustering of patient groups in
only one blood preparation type were also identified (e.g., CA3),
which contributed for the clustering between BMD patients and
controls in serum but not in plasma (Fig 2C and D).
Protein profiles associated with muscular dystrophy
Differences in protein profiles revealed in both serum and plasma
collected at different clinical sites are potentially more robust find-
ings, for not being due to differences in sample preparation and
handling. A nonparametric test was applied to identify protein
profiles that were significantly different between any of the groups,
that is, DMD, BMD, female carriers and healthy controls, and the
resulting lists of proteins with P values < 0.01 were compared, and
the concordant findings in different cohorts were collected in Venn
diagrams in terms of number of common proteins (Fig 3). Both for
serum and plasma, levels for four proteins, CA3, ETFA, MYL3, and
MDH2, were significantly different between DMD patients compared
to controls, as shown in Fig 3A. These proteins allowed separation
of DMD patients from both healthy controls and female carriers.
Protein profiles for MDH2 and MYL3 could also separate between
BMD patients and controls (Fig 3C), whereas CA3 allowed for sepa-
ration of DMD and BMD patients from each other both in plasma
and in serum (Fig 3E).
The classification performances of the identified concordant
protein profiles were visualized by means of receiver operator char-
acteristic (ROC) curves. The best performing protein panel consist-
ing of CA3, ETFA, MYL3, and MDH2 had an area under the curve
(AUC) ≥0.94 for classification between DMD patients and controls
(Fig 3B). The dual panel of MYL3 and MDH2 gave AUC values of
0.77, 0.80, and 0.98 for the classification of BMD patients and
controls in UNEW serum and plasma cohorts and in UNIFE cohort,
respectively (Fig 3D). CA3 alone was also a good classifier for clas-
sification between the DMD and BMD patients especially for the
UNIFE cohort with an AUC of 0.90 as compared to the UNEW cohort
resulting in AUC values of 0.74 and 0.75 in plasma and serum,
respectively (Fig 3F).
For these four proteins concordantly showing statistically signifi-
cant differences, the distribution of MFI values across all individuals
within the muscular dystrophy phenotype groups or controls is
represented in Fig 4. CA3 was targeted in the assay by two different
antibodies: CA3-Ab #1 raised toward the C-terminal part and CA3-
Ab #2 raised toward the N-terminal part of the protein. The protein
profiles generated by these two antibodies correlated well both in
serum and in plasma (Spearman’s q in serum = 0.83, in
plasma = 0.80) (Supplementary Fig S3). Although the obtained
signal intensity ranges differed, similar profiles were obtained for
these two antibodies, with highest signal intensities in the DMD
group, followed by the BMD group and with lowest signal intensities
in the control groups. The other three proteins, MYL3, ETFA, and
MDH2, revealing concordantly significant differences displayed the
same trend as CA3, being more abundant in DMD patients than in
BMD patients and with lowest levels in controls (Fig 4). Furthermore,
the antibody pair targeting MDH2 was one of the 16 well-correlating
antibody pairs (Supplementary Fig S3). We observed that the majority
Table 1. Overview of number of donor types and blood preparation
types retrieved from different clinical sites.
Samples from patients with BMD, DMD, healthy individuals (CONT) and
female carriers of DMD and BMD (FC) collected at four different locations,
that is, at Leiden University Medical Center (LUMC), University of Ferrara
(UNIFE), University of Newcastle (UNEW) and University College London
(UCL) were included in this study, resulting in a total of 345 samples (225
plasma and 120 serum preparations) collected at three different countries
from 245 individuals.
Diagnosis
Sample
origin
Number of
individuals Sample type
Number
of samples
DMD UNEW 60 Plasma 60
Serum 60
LUMC 12 Serum 12
UCL 40 Plasma 40
UNIFE 18 Plasma 18
TOTAL 130 190
BMD UNEW 24 Plasma 24
Serum 24
UNIFE 9 Plasma 9
TOTAL 33 57
FC UNEW 16 Plasma 16
Serum 16
TOTAL 16 32
CONT UNIFE 58 Plasma 58
LUMC 8 Serum 8
TOTAL 66 66
TOTAL 245 345
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Figure 2. Exploratory multi-protein profiles in plasma and/or serum of muscular dystrophy patients and control groups including healthy subjects or female
carriers.
A, C Hierarchical clustering of protein profiles representing the main contributors for the grouping of plasma samples collected from DMD and BMD patients and
controls at UNIFE (A) and UNEW (C).
B, D Hierarchical clustering of protein profiles representing the main contributors for the grouping of serum samples collected from DMD and BMD patients and
controls at LUMC (B) and UNEW (D).
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Figure 3. Identification and classification power of concordant protein profiles separating muscular dystrophy patients from control groups.
A, C, E Venn diagrams illustrate the number of proteins revealing significant differences (P value < 0.01) in different sample cohorts and blood preparation types for
group comparisons between DMD patients and controls (A), BMD patients and controls and (C) DMD and BMD patients (E).
B, D, F Classification power of these individual or combined protein profiles are represented on ROC curves. DMD patients and control groups were classified based on
the panel composed of CA3, ETFA, MYL3 and MDH2 (B). A panel composed of MYL3 and MDH2 classified BMD patients and control groups (D) whereas CA3 alone
classified DMD and BMD patients (F).
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of the ‘outliers’ in these boxplots were BMD patients, in line with
the generally higher degree of heterogeneity within BMD in terms of
clinical phenotype as compared to DMD (Fig 4).
The comparison across DMD, BMD, and control groups revealed
three more potentially interesting proteins, TNNT3, CK, and ETFB
(also summarized in Table 2). Interestingly, the profile for ETFB
showed an opposite trend (Fig 4) compared to other proteins includ-
ing ETFA, which belongs to the same heterodimeric protein complex
as ETFB. A negative correlation was revealed between the signal
intensities for antibodies targeting these two proteins in DMD and
BMD groups as compared to controls (Supplementary Table S2).
The relationship between ETFA and ETFB was further analyzed by
calculation of the ETFB/ETFA MFI value ratios for all the different
sample groups and blood preparation types. Both in serum and in
plasma, the ratios were highest in the control groups followed by
the BMD patients and even lower in DMD (Supplementary Fig S6).
Fitting a linear model revealed a statistically significant association
between the change of ETFB/ETFA ratio and severity of the pheno-
type, in both serum and plasma (Fig 5).
Elevated levels of these seven proteins in blood from patients
with muscular dystrophy can be explained by tissue leakage due to
sarcolemmal disruption as a consequence of muscle contraction. To
confirm that these proteins are present in healthy skeletal muscle
and recognized by the antibodies used, immunohistochemical stain-
ing of tissues was performed (Supplementary Fig S7). The antibod-
ies against CA3, MYL3, and TNNT3 selectively stained skeletal
muscle, whereas those against MDH2, ETFA, and ETFB stained in
addition various other tissue types (accessible through the Human
Protein Atlas portal). In skeletal muscle, antibodies against CA3,
MYL3, and TNNT3 stained the cytoplasm of myocytes, whereas
those against MDH2, ETFA, and ETFB showed a granular cytoplas-
mic staining pattern, indicative of mitochondrial localization. MYL3
and TNNT3 showed strong staining of a subset of muscle fibers.
The strong and muscle-specific staining of CA3, MYL3, and TNNT3
in healthy tissue indicates that detection of increased levels of these
targets in blood samples of muscular dystrophy patients originates
from the muscle, as these targets are not expressed in other tissues.
In order to further investigate the hypothesis that levels of
muscle-specific proteins might be higher in serum/plasma of DMD
and BMD patients, we dissected the protein profile trends across
DMD, BMD, and CONT/FC groups for all of the muscle-specific
targets included in our analysis. Out of 315 protein targets, 112 had
been included in the study due to positive immunohistochemical
staining of the antibodies in muscle tissue. These 112 ‘muscle-
specific’ proteins were targeted by 153 antibodies. Performing a
SOTA cluster analysis across DMD, BMD, and CONT/FC groups
within UNEW and UNIFE cohorts for each of these 153 protein
profiles revealed protein profile trends being ‘DMD increased’ and/
or ‘BMD increased’ as compared to the control groups (Supplemen-
tary Fig S8). In the UNIFE cohort, these were a total of 65 proteins
(targeted by 73 antibodies), and in UNEW plasma and serum
cohorts, there were a total of 62 proteins (targeted by 74 and 73
antibodies, respectively). The combined collection of these three
sets of ‘DMD/BMD increased’ proteins consisted of 94 (out of 112)
targets, and the intersection of these 3 sets consisted of 28 targets,
including the above highlighted candidates MYL3, CA3, MDH2,
ETFA, as well as dystrophin (DMD) or actinin 2 (ACTN2). Presum-
ably, due to small sample sizes, not all of these protein profiles
reached statistically significant difference levels concordant for both
sample types in group comparisons. Nevertheless, almost 85% of
them showed indeed in at least one cohort or sample type a protein
profile trend, supporting increased leakage of muscle-specific
proteins into circulation due to tissue damage in DMD and BMD
patients.
Association of identified protein profiles with disease
development and clinical parameters
It is known that the health status of both DMD and BMD patients
deteriorates with age, but at different rates. We addressed the ques-
tion whether for any of the identified seven proteins, there is a
correlation between protein levels and patient age and summarized
this in Supplementary Table S3. Within the DMD group, for all
targets except ETFB, there was a decrease with age. Particularly, the
levels of MYL3, ETFA, and MDH2 revealed a strong decrease with
age as compared to CA3, TNNT3, and CK (Supplementary Table
S3). Within the BMD group, CA3 decrease did not correlate with
age. Decreases in MDH2 and MYL3 correlated with age to a less
degree in the BMD group in comparison with the DMD group. Most
importantly, the correlations for these targets were much lower or
close to zero in female carriers, and there was no correlation with
age for any of the targets in the healthy controls.
Besides patient age, there are other hallmarks of disease progres-
sion and deterioration of muscular function that are rigorously
monitored and used to assess health status of DMD patients. These
include loss of ambulation, respiratory insufficiency, and cardiac
dysfunction. Analyzing the protein profiles within the DMD cohorts
by hierarchical clustering showed that the ambulant and non-
ambulant DMD patients could be separated from each other
(Supplementary Fig S9). Five of the seven previously mentioned
proteins, CA3, MDH2, MYL3, ETFA, and TNNT3, contributed to the
statistically significant discrimination of ambulant and non-ambu-
lant DMD patients, both in serum and in plasma (Fig 6A). Addition-
ally, a cytoplasmic protein, beta-enolase (ENO3), expressed in
striated muscle tissue, revealed significantly different profiles
between non-ambulant and ambulant DMD patients. The signal
intensity levels for all of these six protein targets were decreased in
non-ambulant patients in comparison with ambulant patients
(Supplementary Fig S10A). Since the age distribution in the DMD
cohorts was broad, we have defined and compared two smaller age-
matched sub-groups of DMD patients from the UNEW cohort; one
for ambulant patients and one for non-ambulant patients with mean
age of 11.6 and 13.8, respectively. This comparison revealed the
same trends for the six proteins, namely that the signal intensity
Figure 4. Boxplots representing the seven protein profiles significantly differing between muscular dystrophy patients and control groups.
Each boxplot represents the MFI values for CA3 (targeted by two different antibodies), MDH2, MYL3, ETFA, ETFB, TNNT3, and CK in plasma and/or serum of muscular dystrophy
patients and control groups. Green and yellow boxes in different cohorts illustrate DMD and BMD patients, respectively, whereas the red boxes illustrate healthy controls and
blue boxes the female carriers of DMD/BMD. For each sample group, the box-and-whisker plot represents MFI values within lower and upper quantile (box), the median
(horizontal line within box), percentiles of 5 and 95% (whiskers) and outliers (dots).
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levels decreased within the DMD patient group with loss of ambula-
tion (Supplementary Fig S11). Next, the classification performance
of these six proteins in serum and plasma samples of ambulant and
non-ambulant UNEW and UCL cohorts was assessed. As indicated
by the AUC values ≥ 0.91, sub-panels consisting of the seven anti-
bodies targeting these six proteins allowed a good classification
between ambulant and non-ambulant DMD patients (Fig 6B).
Within the ambulant patient group from UNEW, the protein profiles
showed little correlation with the NorthStar Ambulatory Assessment
(NSAA) score (data not shown) (Mazzone et al, 2013). The limited
number of patients (27) included in the analysis, and the complexity
of the NSAA scoring system, which comprises assessment of 17
different activities related to gross motor function, might obscure
subtle differences in protein profiles and highlights the need of
detailed patient data recording in connection with sample retrieval.
We also compared the protein profiles for status of ventilation in
order to identify protein profiles differing significantly between
ventilated and non-ventilated DMD patients, all with an age above
14. Here, 16 ventilated patients (three ambulant and 13 non-
ambulant) with an average age of 18 and 11 non-ventilated patients
(all non-ambulant) with an average age of 21 from the UNEW
cohort were included in the analysis. MDH2, ETFA, and TNNT3
revealed significantly higher MFI values in ventilated DMD patients
as compared to non-ventilated DMD patients (Fig 6C and Supple-
mentary Fig S10B). In addition to these three proteins, PPM1F
(protein phosphatase 1F), COL6A1 (collagen alpha-1(VI) chain),
and LCP1 (plastin-2) also contributed for the separation between
ventilated and non-ventilated patients. Based on selected combina-
tion of smaller panels of these six targets, the ROC curve analysis
resulted in AUC values ≥ 0.94 in plasma and serum (Fig 6D). Since
for this analysis the number of patients in each group was relatively
small, these protein profiles need to be further investigated in terms
of their potential predictive value for respiratory dysfunction. We
also did a similar comparative analysis between small groups of
DMD patients with and without cardiac failure, but the statistical
analysis revealed no concordant and statistically significant
differences (data not shown).
One important factor, which potentially could influence the
protein profiles in serum and plasma of DMD patients, is the treat-
ment status of the patients. For instance, in the UNEW cohort, the
majority of DMD patients were treated with steroids (deflazacort or
prednisolone), whereas some had never been treated with any ster-
oids. A multi-group comparison between these two sub-groups of
patients and female carriers showed that the levels for CA3, MDH2,
MYL3, ETFA, and TNNT3 were still elevated in both steroid-treated
and non-treated patients in comparison with female carriers (Fig 7).
Patient age distribution and variation in ambulation status make it
yet difficult to investigate the effect of treatment outcome. Further-
more, lack of more detailed information about the patient response
to treatment or treatment outcome measures highlights the need to
collect longitudinal patient samples to investigate the further value
of the identified proteins as clinical biomarkers.
Discussion
In this study, we have investigated the levels of proteins in blood-
derived samples of patients affected by the rare disease of muscular
dystrophy. The sample set was built from four cohorts collected at
different clinical sites within the framework of the EU FP-7 project
BIO-NMD. To determine the protein profiles in muscular dystrophy
patients and controls, a high-throughput and multiplexed antibody
suspension bead array setup was used in combination with antibod-
ies generated by the Human Protein Atlas. In the context of muscu-
lar dystrophy, our study comprised a large set of samples, and
among the 315 proteins studied, eleven were identified as potential
candidates for discriminating between controls and muscular
dystrophy patients and/or between the different phenotypes of
muscular dystrophies, as well as between patients demonstrating
different degrees of disease progression.
Protein biomarker discovery studies in blood-derived samples
generally rely on findings revealed in one blood preparation type by
screening a sample cohort from a single collection site. Yet, as
demonstrated previously (Schwenk et al, 2010; Qundos et al, 2013;
O’Neal et al, 2014) and in the presented study, different blood prep-
aration types cause proteins to be detected differentially. Further-
more, despite the use of standardized sample collection, handling
and storage protocols, it is difficult to retain identical conditions at
and during transport from different clinical sites, where even subtle
fluctuations might cause variations in the downstream analysis. To
exclude the possibility that the findings are associated with a cohort
of a specific origin or limited only to one blood preparation type, it
is very valuable to base the findings on independent sample cohorts
collected at different clinical sites, which ensures robustness of the
findings at a very early stage. In line with this, the protein profiles
we have denoted here as candidates were mainly selected and high-
lighted based on concordance of statistically significant differences
revealed for these targets in more than one sample cohort and in
both blood preparation types.
The utilized assay platform offers the possibility of generating
hundreds of protein profiles in hundreds of patient samples in a
single analysis, allowing for an effective exploration of potential
candidates. The semi-automated workflow we developed for anti-
body coupling allows a very time-efficient generation of bead arrays
consisting of up to 384 antibodies. While consuming only few
microliters of crude plasma sample for a multiplexed profiling of
hundreds of proteins, the lower limit of detection of this assay setup
is in the higher pg/ml to lower ng/ml range (Schwenk et al, 2010).
This allows not only for detection of proteins expected to be in
plasma, such as CA3 with an average concentration of approxi-
mately 10 ng/ml (Mokuno et al, 1985; Ohta et al, 1991) or CK with
a reference limit around 3–5 ng/ml (Apple et al, 2003), but presum-
ably also for analysis of leakage products (Anderson & Anderson,
2002) from the muscle tissue.
The missing dystrophin has been shown to affect the composi-
tion of the muscle proteome, in particular the abundance of proteins
involved in energy metabolism, muscle fiber contraction and stress
response (Gardan-Salmon et al, 2011; Guevel et al, 2011; Carberry
et al, 2012; Holland et al, 2013). Furthermore, due to its association
with the transmembrane glucoprotein complex and its function,
dystrophin when absent impairs the link between the intracellular
contraction apparatus and the plasma membrane (Le Rumeur et al,
2010). Disruption of this link causes leakage of proteins from
muscle fibers as a consequence of sarcolemmal damage during
muscle contraction (Zweig et al, 1980; Hutter et al, 1991; Menke &
Jockusch, 1995; Straub et al, 1997; Rando, 2012) and/or dysregulation
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of the vesicular transport (Duguez et al, 2013). We therefore
hypothesized that muscle proteins released into the bloodstream
could function as indicators of patient phenotype and/or disease
severity in muscular dystrophies. As hypothesized, we observed
that 85% of the antibodies toward muscle-specific proteins
revealed in at least one cohort or sample type a protein profile
trend supporting increased leakage of muscle-specific proteins into
circulation due to tissue damage in DMD and BMD patients as
compared to controls. Presumably due to small sample sizes, not
all of these protein profiles revealed statistically significant differ-
ences concordant for both sample types in group comparisons. Yet,
statistically significant and concordantly elevated levels were
Table 2. Summary of eleven identified blood marker candidates within muscular dystrophies and their level of statistical significance within
various group comparisons.
For each protein target, P values < 0.01 revealed in group comparisons are highlighted in light blue and P values < 0.001 are highlighted in dark blue.
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Figure 5. Varying ETFB/ETFA ratios in plasma/serum of muscular dystrophy patients and control groups.
A linear model was fit to the ETFB/ETFA level ratio in plasma/serum ofmuscular dystrophy patients and control groups, revealing a statistically significant association between
the change of ETFB/ETFA ratio and the different diagnosis categories in serum (P value for linear model = 3e-07) and plasma (P value for linear model = 1e-14).
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revealed for CA3, MYL3, and MDH2 in serum and plasma of
DMD patients compared to healthy controls or female carriers. In
comparison with these proteins, levels of CK, which has been
used for confirmation of diagnosis of muscle wasting diseases for
several decades (Mendell et al, 2012), were also found to be
increased in patients, but with less degree of concordance and
statistical significance, yet still supporting the technical validity of
our approach.
The proposed mechanisms by which these muscle proteins are
released into the bloodstream are based on impaired secretion and/
or tissue leakage (Lippi & Banfi, 2009; Brancaccio et al, 2010;
Duguez et al, 2013). Mdx myotubes have been reported to release
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Figure 6. Association of protein profiles with ambulation status and respiratory insufficiency.
A, C Venn diagrams illustrate the number of proteins revealing significant differences (P value < 0.01) in group comparisons between ambulant (AMB) and non-
ambulant (Non-AMB) DMD patients (A) and in ventilated and non-ventilated DMD patients (C).
B, D ROC curves represent the classification power of a panel composed of CA3, ENO3, ETFA, MDH2, MYL3, and TNNT3 profiles between ambulant and non-ambulant
DMD patients in UCL plasma cohort and UNEW plasma and serum cohorts (B). Classification of UNEW ventilated and non-ventilated patients was based on a
panel including MDH2, PPM1F, ETFA, and TNNT3 for plasma and a panel including MDH2, PPM1F, COL6A1, and LCP1 for serum (D).
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proteins such as MYL1 and MYL3 by lysosomal-associated
membrane protein, LAMP1 vesicle mediated export due to an
impaired secretion mechanism (Duguez et al, 2013). In contrast,
CA3 has not been proven to be secreted through vesicle and could
still enter the blood stream through tissue leakage due to membrane
disruption. To elucidate the mechanisms by which the identified
markers enter the blood stream requires additional experiments to
establish in which way the transport is achieved. This could add
great value to the understanding of the pathophysiological changes
undergoing in muscles and the evaluation of these markers for clini-
cal use.
Among the highlighted candidates, CA3 had been reported two
decades ago to be elevated in serum of DMD patients but has not
been re-evaluated since then (Carter et al, 1983). Our data further
showed that CA3, which was targeted by two different antibodies in
our assay, discriminated not only between DMD patients and
healthy controls but also between the DMD and BMD clinical
phenotypes. This protein has recently been reported to be increased
in muscle of dystrophic chicken as compared to normal muscle
(Nishita et al, 2012). Interestingly, carbonic anhydrase inhibitors
have shown to have positive effects in animal models of dystrophin-
opathies, suggesting they might be potentially explored for human
therapy (Giacomotto et al, 2009). Expression of CA3 in different
tissues, muscles and types of muscle fibers might explain the origin
of the target detected in the bloodstream. CA3 is expressed in few
tissues and therefore considered to be a more specific and sensitive
marker for muscular dystrophies in comparison with CK, which is
more ubiquitously expressed (Shima, 1984; Va¨a¨na¨nen et al, 1988;
Harju et al, 2012). CK abundance into the blood does not correlate
with deterioration of specific muscle fibers upon tissue damage
(Shima, 1984; Osterman et al, 1985; Va¨a¨na¨nen et al, 1988), whereas
CA3 does. CA3 is preferentially expressed at high levels in type I
muscle fibers and is considered to be a marker for type 1 muscle
fibers deterioration (Shima et al, 1983; Brancaccio et al, 2010).
Consequently, elevated CA3 serum levels might reflect deterioration
of skeletal muscles enriched in type I muscle fibers, such as the
soleus muscle with a high CA3 content, rather than muscles
enriched in type IIa and IIb fibers with low CA3 content (Fre´mont
et al, 1988). The soleus muscle in patients with DMD is hypothe-
sized to exert more power during ambulation, which causes hyper-
trophy or pseudohypertrophy and decrease in muscle mass (Cros
et al, 1989). Studies in healthy individuals showed that CA3 is accu-
mulated into the blood as a consequence of skeletal muscle injury
(Va¨a¨na¨nen et al, 1990; Brancaccio et al, 2010) and vigorous physi-
cal exercise (Takala et al, 1989) in a similar way as CK. Since
continuous stimulation of muscles leads to increased expression of
CA3 mRNA, it is difficult to conclude whether the elevated serum
levels in NMD patients are due to muscle fiber replacement with
connective tissue, increased expression of CA3 or both (Brownson
et al, 1988). However, increased tissue expression due to other
pathological conditions than muscular dystrophy, such as aging
(Staunton et al, 2012), obesity and treatment with insulin or leptin
(Alver et al, 2004), might affect serum levels of CA3. Thus, each
and one of these effectors must be considered during follow-up
studies.
There are several lines of evidence suggesting that the energy
metabolism of dystrophic muscle is disturbed in DMD (Ikehira et al,
1995), which might explain the elevated ETFA levels in serum and
plasma of DMD patients. In contrast, ETFB, interacting with ETFA
to build a complex involved in electron transfer from mitochondrial
flavin-containing dehydrogenases to the respiratory chain, showed
an opposite trend. ETFB was the only protein among the identified
markers that revealed decreased levels in both plasma and serum of
DMD patients as compared to BMD patients and controls. Our find-
ings regarding the negative correlation between ETFA and ETFB and
the gradual change of ETFB/ETFA ratio in DMD and BMD patients
and controls could be the consequence of a relation between the
accumulation of ETFA and dissipation of ETFB in patients with
DMD and BMD as compared to controls. Yet, this opposite trend in
abundance of ETFB and ETFA has not been reported previously,
and the underlying reason for this finding cannot be explained at
this point and remains to be investigated further.
Abundance of three serum proteins MMP9, metalloproteinase
inhibitor 1 (TIMP1), and fibronectin (FN1) has very recently been
shown to correlate with disease progression in patients affected by
muscle dystrophy (Brancaccio et al, 2010; Nadarajah et al, 2011;
Martin et al, 2014). In addition, potential protein markers for treat-
ment outcome were identified in mdx mice plasma, for example, the
coagulation Factor XIIIa (FXIIIa), leukemia inhibitory factor (LIFr),
glutathione peroxidase 3 (GPX3), apolipoprotein E a (ApoE a), and
b actins (ApoE b) (Alagaratnam et al, 2008; Colussi et al, 2009).
Among these previously reported protein biomarkers, MMP9 was
included in our target list (Nadarajah et al, 2011); however, the
elevated levels of MMP9 in DMD patients compared to BMD patients
were revealed only in plasma samples from a single clinical site and
could not be confirmed in serum or in the other plasma cohorts.
Duchenne and Becker muscular dystrophies are characterized by
progressively impaired muscular function with increasing age and
muscular wasting. The majority of the protein profiles identified in
this study showed a decrease with age in DMD patients, whereas
only MDH2, MYL3 and ETFA showed a decrease with age in the
BMD patients, although the age range in the latter group was wider.
The rapid disease development and progressive muscle weakness
experienced by DMD patients might be reflected in the strong
decrease, considering the fact that there was no difference due to age
in the control group. Nevertheless, this still highlights the inherent
difficulty of distinguishing the effect of age and the effect of disease
progression on protein levels in muscular dystrophies, underlining
the need of ideally recruiting age-matched control subjects.
Establishment of the clinical phenotype, monitoring of disease
progression, and disease management in muscular dystrophies
involve assessment of motor functions, such as ability to walk and
climb and assessment of respiratory capacity and cardiac function.
We performed comparative analyses based on these clinical parame-
ters to identify protein profiles potentially associated with such
parameters. Within the DMD patient group, besides CA3, ETFA,
MDH2, and MYL3, two other proteins, TNNT3 and ENO3, revealed
significantly different profiles between the ambulant and non-
ambulant DMD patients. Both of these proteins are muscle-specific
proteins, ENO3 being involved in muscle development and regener-
ation (Ohara et al, 2006), whereas TNNT3 is involved in striated
muscle contraction. Expression of TNNT3 has been previously
reported to be decreased in muscle of dystrophic dog in comparison
with healthy dogs (Gomes et al, 2004; Guevel et al, 2011). Consider-
ing the comparative analysis regarding ventilation in the UNEW
DMD cohort, the proteins LCP1, COL6A1, and PPM1F together
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with TNNT3, ETFA, and MDH2 exhibited decreased levels in both
serum and plasma of non-ventilated DMD patients in comparison
with those using a respiratory aid. COL6A1 has previously been
linked to muscle regeneration and associated with other myopa-
thies (Urciuolo et al, 2013), whereas LCP1 is a bundle protein
linking actin filaments together and associated with autoimmune
disease (Delanote et al, 2005). It should be noted that, while
increased levels of skeletal muscle proteins in blood-derived
samples indicate an increased muscle fiber breakdown and tissue
leakage, increased levels of proteins, such as COL6A1 and LCP1,
might be related to increased protein expression possibly indicat-
ing augmented connective tissue remodeling and inflammation.
Interestingly, patients with respiratory insufficiency have lower
levels of TNNT3, MDH2, and ETFA than the ones without,
suggesting that patient sub-groups within the DMD cohort could
be identified.
The presented discoveries from our screening efforts require
further translation into assay systems that can be used in a clini-
cal environment. This not only includes to develop a clinically
robust test, preferably in a sandwich immunoassay format, but
also to challenge the clinical sensitivity of this test with indepen-
dent sets of samples. While the latter certainly is a challenge for
rare diseases, we have yet recently shown a path of successfully
translating ‘discovery’ assays into clinically more applicable tests
(Qundos et al, 2014). Such a path would include (i) collecting
commercially available mono- and polyclonal antibodies and
generating monoclonal antibodies for targets with no commercial
antibody availability, (ii) epitope-mapping of these antibody
collections on high-density peptide arrays (Buus et al, 2012), and
(iii) testing multi-antibody sandwich assays to identify matching
pairs of these antibodies with distinct epitopes revealing a good
assay sensitivity. From a clinical point of view, the most urgent
need is to monitor disease progression in dystrophinopathies.
Besides, there are also intermediate cases of DMD/BMD patients
where genetic testing does not provide a clear diagnose. There-
fore, although all the eleven candidates we have highlighted
merit further investigation, initially, a marker panel consisting of
CA3, MDH2, MYL3, TNNT3, and ETFA could be selected for
development and further challenging with new sample material
of such a 5-plex sandwich assay system as profiles for this set
of five proteins would allow for an assessment of both the
DMD/BMD and the ambulation status.
Although the candidate protein profiles we have highlighted here
are not constrained by a certain blood preparation type, subsequent
analyses of larger sample cohorts might indeed unveil whether any
of these two blood preparations is preferable. For a future imple-
mentation of a marker panel, particular sample collection protocols
and guidelines need therefore to be assessed and defined in order to
achieve best and most robust assay performance. Such guidelines
could then of course be applied across different cohorts and interna-
tional study sites. Besides, levels of muscle proteins in the blood
might be influenced by many parameters, such as overall muscle
mass, amount of ongoing necrosis, and levels of physical activity as
reflected by decreasing levels of muscle proteins in blood from older
DMD patients. For future efforts in collecting and screening muscu-
lar dystrophy-related sample cohorts, it is crucial to clinically strat-
ify patient cohorts according to age in combination with clinical
phenotypes such as status of ambulation and/or respiratory function
to fully elucidate these relationships. In addition, longitudinal stud-
ies in carefully characterized patient cohorts would support the
evaluation of the utility of the identified protein profiles. Also, a
matched analysis of muscle fibers and tissue with blood-derived
samples would contribute for a better understanding of the origins
and mechanisms leading to the proteins being present in blood.
Matched tissue and blood samples are though not routinely
collected and will require initiation of new sampling efforts with
consent of patients and their guardians. Taken together, the
presented study provides an important starting point for even more
dedicated efforts within the muscular dystrophy community that
will aim at elucidating disease pathogenesis further in multi-disci-
plinary collaborations including several centers with an ultimate
aim of developing translated assays and assessing their performance
at multiple clinical sites.
In conclusion, using an antibody-based proteomic profiling
approach to screen geographically dispersed and independent
cohorts of muscular dystrophy, we were able to identify proteins in
blood that are involved in muscle function and energy metabolism.
This demonstrated that other proteins than CK can be found accu-
mulated in blood presumably as a consequence of muscle fiber
injury or tissue leakage in muscular dystrophies. Our quest for
potential, easily accessible blood marker candidates revealed pres-
ence of proteins that were indicators of disease phenotype and
severity, making them key candidate proteins for novel clinical tests
for diagnosis and management of muscular dystrophies. Further-
more, our approach demonstrated the possibility of gaining new
insights into proteins altered in the circulation of patients with rare
diseases even when only limited number and volumes of samples
are available. Therefore, the affinity-proteomics approach we
presented here offers a great promise for many other rare disorders
with an urgent need for blood-based protein markers, and it could
pave the way for further combined efforts to tackle the challenges
posed by diseases with rare phenotypes.
Materials and Methods
Sample collection and study design
Serum and plasma samples were collected at four different clinical
sites according to a collection protocol adopted within the framework
of the BIO-NMD EU-FP7 program: Leiden University Medical Center
in the Netherlands (LUMC), University of Ferrara in Italy (UNIFE)
Figure 7. Protein profiles of steroid-treated and non-treated muscular dystrophy patients and female carriers.
Boxplots represent the five protein profiles across steroid-treated and non-treated DMD patients and female carriers. MFI values for MYL3, MDH2, CA3, ETFA, and TNNT3 in
plasma and serum of steroid-treated, non-treated DMD patients and female carriers from UNEW are shown, where dark green, light green, and blue boxes represent treated
DMD patients, non-treated DMD patients and female carriers, respectively. For each sample group, the box-and-whisker plot represents MFI values within lower and upper
quantile (box), the median (horizontal line within box), percentiles of 5 and 95% (whiskers) and outliers (dots).
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and Newcastle University (UNEW) and University College of London
(UCL) in United Kingdom. According to the standardized protocol
established by the consortium, a total of 120 serum samples were
collected at two of the sites and 225 plasma samples were collected at
three of the sites (Table 1). Retrieval, storage, and use of samples
were performed according to national policies regarding ethical treat-
ment of human subjects. All cohorts included samples from patients
with a genetically confirmed diagnosis of DMD but only the cohorts
from UNIFE and UNEW included samples from individuals diagnosed
with BMD. Controls were included in three cohorts: healthy individu-
als in the LUMC and UNIFE collections and female asymptomatic
carriers in the UNEW collection. The sample collection from UNEW
included matched serum and plasma samples from the same individ-
uals. Together with the samples, information about gender, age, diag-
nosis, status of ambulation, and other relevant clinical parameters
was assembled (Supplementary Dataset File S1). Collection of
samples from patients and their use for research have been ethically
approved by Ferrara Hospital Ethical Committee, Hammersmith
Research Ethics committee, NRES Committee North East—Newcastle
& North Tyneside 1 and LUMC Commissie Medische Ethiek and
performed according to the principles set out in the WMA Declaration
of Helsinki. Information about the samples was used as anonymized
and aggregate data.
Selection of candidate targets and design of the antibody array
A generous list of protein targets potentially associated with
dystrophinopathies was assembled based on experimental
evidence and/or theoretical analysis and annotated using the Path-
way Studio software (Ariadne Genomic, Inc.) (Yuryev et al, 2006;
Kotelnikova et al, 2012). The list included a total of 959 unique
genes assembled based on 402 genes with experimental evidence
for being associated with DMD, 248 genes expressed in healthy
muscle, and 431 genes associated with muscular dystrophy as
judged by literature search and Gene Ontology. For each gene,
information about (i) experimental evidence for association with
DMD, (ii) experimentally confirmed expression in normal skeletal
muscle, (iii) involvement in pathways and cellular processes and/
or Gene Ontology terms related to muscular dystrophy, and (iv)
genes reported to be linked to DMD and other muscular dystro-
phies in the literature was compiled. The number of experimental
evidence was scored and weighted to 40, 10, 2.5, and 10%,
respectively. Characteristics of the corresponding gene products
regarding secretion, detectability in serum and/or plasma, and
evidence for expression in humans were also used to prioritize
the genes. These characteristics were scored and weighted with
2.5, 5, and 2.5%, respectively. Each parameter was than multi-
plied by the given weight, and the weighted scores were summed.
Furthermore, availability of antibodies toward these targets was
checked in the Human Protein Atlas repository, and at least one
antibody was selected for each target. The list was then supple-
mented with antibodies targeting known serum and plasma
proteins, resulting in a set of 384 antibodies directed to 315 differ-
ent proteins (Supplementary Dataset File S2). A detailed overview
on number of unique protein targets and number of antibodies
per target is provided in Supplementary Table S4. All antibodies
were characterized and validated within the Human Protein Atlas
framework on antigen microarrays, Western blots, and tissue
microarrays according to established protocols (Uhle´n et al, 2010;
Asplund et al, 2012).
Generation of antibody suspension bead arrays
The concentration of all the antibodies was normalized using a
liquid handling system (EVO150, TECAN) by diluting 1.6 lg of
each antibody into 100 ll of 0.1 M 2-(N-morpholino)ethanesul-
fonic acid (MES) buffer (pH 4.5). Antibodies were then coupled to
carboxylated, color-coded magnetic beads (MagPlex-C, Luminex
Corp.) as per previously developed antibody-coupling protocols
(Schwenk et al, 2008). In brief, 5 × 105 beads per bead identity
were distributed across 96-well microtiter plates (Greiner BioOne),
washed and re-suspended in phosphate buffer (0.1 M NaH2PO4,
pH 6.2) using a plate washer (EL406, Biotek). Bead surfaces were
activated by addition of 0.5 mg 1-ethyl-3(3-dimethylamino-propyl)
carbodiimide (Pierce) and 0.5 mg N-hydroxysuccinimide (Pierce)
in 100 ll phosphate buffer. After 20 min incubation on a shaker
(Grant Bio), beads were washed with 0.1 M MES buffer.
Pre-diluted antibodies were added to the beads using a liquid
handler (SELMA, Cybio) and incubated for 2 h at RT. Three
additional bead identities were functionalized either with 1.6 lg of
rabbit IgG (Bethyl), 1.6 lg of in-house produced recombinant albu-
min binding protein, or without addition of any protein providing
assay quality controls. Antibody-coupled beads were then washed
3× in PBS-T (1 × PBS, 0.05% Tween20), re-suspended in 50 ll of
a storage buffer (Blocking Reagent for ELISA, Roche Applied
Science) supplemented with 0.1% (v/v) ProClin (Sigma-Aldrich),
and stored overnight at 4°C. A 384-plex antibody suspension bead
array was prepared by combining equal volumes of each bead
identity and followed by sonication for 3 min (Branson Ultrasonic
Corp.). The bead array was stored at 4°C until further use. The
coupling of each antibody on the beads was confirmed via
R-Phycoerythrin-conjugated donkey anti-rabbit IgG antibody
(Jackson ImmunoResearch) before performing the assay with
patient samples.
Pre-analytical preparation and labeling of plasma/serum samples
Neat serum/plasma samples were centrifuged for 10 min at
3,000 × g and aliquoted into microtiter plates with a liquid handling
system (Freedom EVO150, TECAN). Three microliters of each
sample was diluted in 22 ll of 1xPBS in new microtiter plates
according to a plate layout design. This design allowed a random-
ized and balanced distribution of samples across multiple plates in
terms of both categorical variables, namely sample origin (UNEW/
UNIFE/UCL/LUMC), blood preparation type (serum/plasma), and
disease category (DMD/BMD/Control), and the quantitative variable
of age tested by ANOVA test. The diluted and randomized samples
were labeled utilizing biotin as previously described (Schwenk et al,
2008). Briefly, the diluted samples were incubated over 2 h at 4°C
with a 10-fold molar excess of NHS-PEG4-Biotin (Pierce) calculated
based on the assumption of an average molecular weight of 60 kDa
and a plasma/serum total protein concentration of 60 mg/ml. The
labeling reaction was quenched by addition of a 250-fold molar
excess of 0.5 M Tris–HCl (pH 8.0) over biotin. After incubation with
Tris–HCl for 20 min at 4°C, samples were stored back to !80°C until
usage.
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Assay procedure and read-out
The biotin-labeled samples were diluted 1:50 using a liquid
handler (SELMA, CyBio) in an assay buffer composed of 0.5%
(w/v) polyvinylalcohol and 0.8% (w/v) polyvinylpyrrolidone
(Sigma) in 0.1% (w/v) casein (Sigma-Aldrich) in PBS (PVXC)
supplemented with 0.5 mg/ml rabbit IgG (Bethyl), yielding a total
sample dilution of 1:500. Samples were then heat-treated at 56°C
for 30 min and cooled to 20°C for 15 min in a thermo-cycler
(Applied Biosystems). Then, 45 ll of heat-treated samples was
added to 5 ll of the antibody suspension bead array distributed
into a 384-well microtiter plate (Greiner BioOne). Subsequent to
16-h incubation on a shaker (Grant) at RT, beads were washed
with 3 × 50 ll PBS-T using a plate washer (EL406, Biotek),
followed by an incubation for 10 min with 50 ll of 0.4% parafor-
maldehyde in PBS-T. Beads were washed with 50 ll PBS-T and
incubated with 50 ll of 0.5 lg/ml R-phycoerythrin labeled strepta-
vidin (Invitrogen) in PBS-T for 20 min. Finally, beads were
washed 3 × 50 ll PBS-T before addition of 60 ll of PBS-T for
measurement in the FlexMap3D instrument (Luminex Corp.) utiliz-
ing the Luminex xPONENT software. At least 50 events per bead
ID were counted, and binding events were displayed as median
fluorescence intensity (MFI).
Data analysis and statistics
All data analysis and visualizations were performed using R (Ihaka
& Gentleman, 1996), unless otherwise indicated. MFI values were
pre-processed, separately for serum and plasma, using probabilistic
quotient normalization (PQN) (Dieterle et al, 2006) accounting for
any potential sample dilution effects (Kato et al, 2011), and the
PQN-normalized data were used in the statistical analyses displayed
in the figures and tables. Principal component analysis (PCA) was
performed to confirm that there was no systematic variation in the
dataset driven by sample origin or assay plate and that there were
no outlier samples. Heatmaps with unsupervised hierarchical clus-
tering were generated using the Qlucore Omics Explorer software
v2.3 (Qlucore) for exploratory analysis, which utilizes t-test for two-
group comparisons and F-test for multi-group comparisons as an in-
built statistical filtering functionality. Self-organizing tree algorithm
(SOTA) was applied using the R package ‘cIValid’ (Herrero et al,
2001) on scaled and centered MFI values across DMD, BMD, and
CONT/FC groups for an unsupervised and divisive clustering of
protein profiles across DMD, BMD, and CONT/FC groups. All correla-
tion coefficients were calculated using nonparametric Spearman’s
correlation.
The nonparametric Wilcoxon rank-sum and Kruskal–Wallis
tests were applied to PQN-normalized and log2-transformed data
to calculate P values. Differences in protein profiles between
compared groups were denoted statistically significant if they
concordantly revealed P values < 0.01 in different cohorts and
blood preparation types, without multiple testing correction. The
intersection of proteins revealing P values < 0.01 was identified
by using the R package ‘VennDiagram’ and visualized with Venn
diagrams (Chen & Boutros, 2011). Datasets including only these
intersecting proteins were analyzed using the web-based tool
‘PanelComposer’ (Jeong et al, 2012) employing logistic regression to
compare the classification power of single or different combinations
of proteins, where leave-one-out method was selected as cross-
validation option. Multivariate binary logistic regression was
performed for protein panels suggested by PanelComposer, and
the respective ROC curves were generated using the R package
‘EpiCalc’. For each comparison, proteins with P values < 0.01 and
confirmed by analysis of all relevant cohorts were included in the
test panels. The data have been deposited in the ArrayExpress
database with the accession number E-MTAB-2564.
Supplementary information for this article is available online:
http://embomolmed.embopress.org
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The paper explained
Problem
Young boys affected by Duchenne muscular dystrophy, a rare and
severe genetic disease, are diagnosed using an array of different
genetic, enzymatic, histopathologic and physical tests. These tests
correlate poorly with disease severity and are often affected by other
factors than the disease such as the age, the overall well-being, the
level of understanding, and the ability of the patient to cooperate with
the clinicians. As the disease progresses, patients lose their ability to
walk and stand, making physical tests more difficult and painful to
perform. Another test often used is analysis of muscle tissue biopsies
collected through invasive procedures causing great discomfort to the
patients. New approaches and tests are required to improve clinical
management of muscular dystrophies and accurately determine the
severity of the disease, disease progression, and treatment outcome.
Results
Protein levels in blood show promise for providing clinically relevant
information to monitor patient health status. Comparing levels of
proteins in blood, we identified protein profiles that discriminate
between patients affected by Duchenne muscular dystrophy with
different degrees of severity. Four proteins, carbonic anhydrase III
(CA3), myosin light chain 3 (MYL3), malate dehydrogenase 2 (MDH2),
and electron transfer flavoprotein A (ETFA), are more abundant in
blood from patients with DMD in comparison with healthy individu-
als. The results obtained are in agreement in samples collected from
four clinical sites and concordant in both serum and plasma.
The last two proteins also correlate with the patient ambulation
status and respiratory insufficiency in different subgroups of patients.
Impact
In the context of muscular dystrophies, there is a need for molecular
biomarkers that can be used to determine disease severity and to
monitor disease progression over time. The identified protein markers
are easily accessible and provide information that can improve preven-
tive clinical management of the disease and selection of individualized
treatment regimes. Given the short life expectancy of the patients with
Duchenne muscle dystrophy, development of more accurate tests to
improve clinical management of the disease will have a great impact
on patient life quality. Furthermore, this study represents an important
example for how more insights into proteins altered in the circulation
of patients with rare diseases can be effectively studied across various
clinical sites using affinity-proteomics approaches.
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